SPA
ORIC icon

Sherbrooke Park Advisers’s Oric Pharmaceuticals ORIC Stock Holding History

Sherbrooke Park Advisers’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,911
Closed -$72.1K – 622
2023
Q3 		$72.1K Buy
+11,911
New +$97.6K 0.02% 476

Other funds holding ORIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Sherbrooke Park Advisers's ORIC Position: Q4 2023 in Review

Sherbrooke Park Advisers sold out of Oric Pharmaceuticals (ORIC) in Q4 2023, closing a stake of 11,911 shares — an estimated $72.1K sold.

Sherbrooke Park Advisers first reported a position in ORIC in Q3 2023 and held it in 1 quarter. The position peaked at $72.1K in Q3 2023. 92 funds tracked by Wall St. Rank hold ORIC as of Q4 2023.

  • Sherbrooke Park Advisers reported no remaining Oric Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 11,911 Oric Pharmaceuticals shares in Q4 2023, an estimated $72.1K.
  • Sherbrooke Park Advisers first reported a position in Oric Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Oric Pharmaceuticals position peaked at $72.1K in Q3 2023.
  • 92 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2023.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.